FDA nominee Heidi Overton defends vaccine safety and faces scrutiny over abortion pill in Senate hearing

Senate questioning on vaccine safety

Dr. Heidi Overton, President Donald Trump's nominee to lead the Food and Drug Administration, defended the safety of routine immunizations during her confirmation hearing before the Senate Health, Education, Labor and Pensions Committee on Thursday. Overton testified that the measles, mumps and rubella (MMR) vaccine is safe, effective, and the primary tool to manage the ongoing domestic outbreak. Her statements departed from earlier public assertions by Trump suggesting the MMR shot could be lethal. Committee Chairman Bill Cassidy, a physician from Louisiana, pressed Overton on how she would navigate political interference from the White House, citing unfulfilled commitments from Health and Human Services Secretary Robert F. Kennedy Jr. Overton maintained that she would provide independent counsel while following federal statutory requirements for drug approvals.

Every vaccine on the US market right now is safe and effective according to the FDA.

Scrutiny over abortion pill review

Lawmakers from both parties scrutinized Overton over the regulatory status of mifepristone, a medication used in more than two-thirds of abortions in the United States. In response to questions from Wisconsin Democrat Tammy Baldwin, Overton affirmed that mifepristone remains safe and effective under its current FDA label, though she declined to comment on the outcome of an active agency safety review. Missouri Republican Josh Hawley challenged that position, arguing that defending the existing label undermined the administration's courtroom challenges against Biden-era telehealth distribution rules. Hawley informed reporters following the hearing that he may oppose her confirmation without explicit clarification on the administration's litigation posture. The FDA originally approved mifepristone in 2000, but Kennedy directed the agency to re-evaluate the medication last year following requests from anti-abortion organizations.

Biotechnology priorities and vape regulation

In her opening remarks, Overton called for accelerated drug review timelines to protect American biotechnology leadership from growing competition in China. Maine Republican Susan Collins questioned the nominee over the FDA's August authorization of flavored electronic cigarettes and nicotine pouches, including blueberry, mango, and cappuccino varieties. Industry representatives have also sought regulatory predictability; Genentech senior vice president Fritz Bittenbender stated at a Wednesday event that biotechnology firms require both faster reviews and consistency for therapies already undergoing evaluation. Independent Senator Bernie Sanders pressed Overton on whether she would challenge presidential directives that contradict scientific consensus, to which Overton responded that her long tenure advising Trump earned his trust through robust discussions.

HHS deputy nomination moves forward

Simultaneously on Thursday, the Senate Finance Committee voted 15 to 12 to advance Chris Klomp to a full Senate vote for deputy secretary of Health and Human Services. Klomp, an adviser to Kennedy who leads international drug price negotiations and assisted in selecting Centers for Disease Control and Prevention Director Erica Schwartz, secured support from all panel Republicans and Rhode Island Democrat Sheldon Whitehouse. Senate Finance Committee ranking Democrat Ron Wyden opposed Klomp, pointing to confidential terms in drug price pacts with two dozen pharmaceutical companies and disputed self-employment taxes from 2022 to 2024 related to Klomp's investment firm, the Endurance Companies. Klomp previously testified that the measles outbreak, which began 19 months ago and has infected nearly 6,000 individuals, represents a top public health priority.